In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and ...
The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...
The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...
The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...
Bristol Myers' Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.
Pembrolizumab provided clinical benefit in previously treated advanced clear cell gynaecological cancer (CCGC). A single-arm ...
With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in ...
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback